<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549171</url>
  </required_header>
  <id_info>
    <org_study_id>OGAFSH-01</org_study_id>
    <nct_id>NCT01549171</nct_id>
  </id_info>
  <brief_title>Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)</brief_title>
  <official_title>Pilot Study to Examine Iloprost Can Enhance Human Assisted Reproductive Technology Pregnancy Outcomes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fertility Specialists of Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Origio A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fertility Specialists of Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human fallopian tube secretes high concentration of prostacyclin. Fallopian tube is the site
      for early embryo development. The effect of prostacyclin on human early embryo development is
      waiting to be clarified. The study hypothesis is prostacyclin can enhance early embryo
      development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Huang et al, found that human fallopian tube expresses prostacyclin synthetase and
      cyclooxygenase. These enzyme systems synthesize abundant prostacyclin (PGI2). In the
      fallopian tube PGI2 causes smooth muscle relaxation, possibly facilitating tubal transport of
      gametes and embryos. Huang et al reported that addition of the PGI2 analogue Iloprost to
      embryo culture media significantly enhanced mouse embryo development to the blastocyst and
      complete hatched stages. The implantation and live birth rates of Iloprost cultured embryos
      were significantly better than non-Iloprost embryos in the mouse model. The mean weights of
      fetal mice were not significant different from control group. There was no teratogenic effect
      observed.

      In a previously presented study, the investigators cultured donated frozen human zygotes in
      culture media with and without the addition of Iloprost. The Iloprost treated embryos showed
      significantly better growth rate and morphology, as determined by the size, and grading of
      the trophectoderm and inner cell mass.

      Iloprost is FDA approved for the treatment of pulmonary hypertension. It has a significantly
      longer half-life than native PGI2. Iloprost is a class C pregnancy drug and has not been
      associated with teratogenic effects. This study intends to expand the usage of Iloprost to
      culture embryos.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of embryo sac in uterus under ultrasound</measure>
    <time_frame>5 weeks after embryo transfer</time_frame>
    <description>The competency of embryo is determined by its ability to implant into endometirum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The delivery outcome is the secondary outcome measured.</measure>
    <time_frame>10 months after embryo transfer</time_frame>
    <description>The live birth and the weight and length of baby is examined.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Iloprost</arm_group_label>
    <description>This is the study group with 1 uM Iloprost.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>This is the control group with vehicle (normal saline) only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost</intervention_name>
    <description>supplement in culture medium during culture in the lab. The concentration is 1 uM.</description>
    <arm_group_label>Iloprost</arm_group_label>
    <other_name>Ilomedin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Supplement with vehicle only no Iloprost.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ART cases with age &lt; 40 and without pre-implantation genetic diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ART case

        Exclusion Criteria:

          -  age &lt; 40

          -  no pre-implantation genetic diagnosis procedure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George M Grunert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Obstetrical &amp; Gynecological Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fertility Specialists of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan-Song A Wun, Ph.D.</last_name>
      <phone>713-512-7680</phone>
      <email>awun@obgynassociates.com</email>
    </contact>
    <contact_backup>
      <last_name>George M Grunert, M.D.</last_name>
      <phone>713-512-7760</phone>
      <email>ggrunert@fshivf.com</email>
    </contact_backup>
    <investigator>
      <last_name>Randall C Dunn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Schenk M Leah, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mangal K Rakesh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chauhan R Subodh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wan-Song A Wun, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Battenfeld R, Schuh W, Sch√∂bel C. Studies on reproductive toxicity of iloprost in rats, rabbits and monkeys. Toxicol Lett. 1995 Aug;78(3):223-34.</citation>
    <PMID>7542807</PMID>
  </reference>
  <reference>
    <citation>Grunert GM, Dunn RC, Valdes CT, Schenk LM, Mangal RK, Wun WSA: Prostacyclin agonist (Iloprost) enhances human embryo development. Fertility and Sterility 84:S237, 2005</citation>
  </reference>
  <reference>
    <citation>Huang JC, Arbab F, Tumbusch KJ, Goldsby JS, Matijevic-Aleksic N, Wu KK. Human fallopian tubes express prostacyclin (PGI) synthase and cyclooxygenases and synthesize abundant PGI. J Clin Endocrinol Metab. 2002 Sep;87(9):4361-8.</citation>
    <PMID>12213900</PMID>
  </reference>
  <reference>
    <citation>Huang JC, Wun WS, Goldsby JS, Matijevic-Aleksic N, Wu KK. Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching. Hum Reprod. 2004 Dec;19(12):2900-6. Epub 2004 Oct 15.</citation>
    <PMID>15489241</PMID>
  </reference>
  <reference>
    <citation>Huang JC, Goldsby JS, Wun WS. Prostacyclin enhances the implantation and live birth potentials of mouse embryos. Hum Reprod. 2004 Aug;19(8):1856-60. Epub 2004 Jun 17.</citation>
    <PMID>15205402</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>March 8, 2012</last_update_submitted>
  <last_update_submitted_qc>March 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human ART</keyword>
  <keyword>Prostacyclin</keyword>
  <keyword>Iloprost</keyword>
  <keyword>Pregnancy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 11, 2014</submitted>
    <returned>August 25, 2014</returned>
    <submitted>March 6, 2015</submitted>
    <returned>March 17, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

